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Abstract: We investigated the lipid-lowering effects of methanolic extract of Vernonia 
amygdalina (VA) leaves in rats fed an high cholesterol diet, and compared with a standard hypo-
lipidemic drug, Questran (Qu). The effects of VA on the lipid proﬁ  le were assessed by measuring 
the levels of total cholesterol, triglyceride, low-density lipoprotein (LDL) cholesterol, high-density 
lipoprotein (HDL) cholesterol, lipid peroxidation (LPO), phospholipid, and glutathione (GSH) in 
the plasma and liver of the rats. Administration of cholesterol at a dose of 30 mg/0.3 ml, ﬁ  ve times 
in a week for nine consecutive weeks resulted in a signiﬁ  cant increase (p   0.05) in plasma and 
post mitochondrial fraction (PMF) cholesterol levels by 33% and 55%, respectively. However, 
treatment with extract of VA at doses of 100 and 200 mg/kg caused a dose dependent reduction in 
the plasma and PMF cholesterol by 20%, 23% and 23%, 29%, respectively. Similar reduction in 
cholesterol levels was obtained in Qu-treated rats. Furthermore, VA at 200 mg/kg decreased the 
plasma and PMF LDL-cholesterol levels by 23% and 49%, and also decreased plasma and PMF 
triglyceride levels by 29% and 28%, respectively. Also, VA at 100 and 200 mg/kg caused a dose-
dependent increase in plasma HDL-cholesterol levels by 41% and 59%, respectively. However, 
there were no signiﬁ  cant differences (p   0.05) in the PMF HDL-cholesterol and phospholipid 
levels of the treated rats when compared to hypercholesterolemic rats. There were signiﬁ  cant 
decreases (p   0.05) in the LPO levels of extract-treated rats. Precisely, VA at 100 and 200 
mg/kg decreased the levels of plasma and PMF LPO by 38%, 42% and 35%, 45%, respectively. 
In addition, VA augmented the cholesterol-induced decrease in PMF glutathione levels of the 
rats. Taken together, these results suggest the lipid-lowering effects of VA and, probably serve 
as a new potential natural product for the treatment of hyperlipidemia.
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Introduction
It is known that hypercholesterolemia is a risk factor for cardiovascular diseases (CVD) 
such as atherosclerosis and myocardial infarction, which is a common cause of mortal-
ity and morbidity (Wald and Law 1995; Krieger 1998). Although several factors, such 
as life style, a diet rich in cholesterol, age and hypertension, have been reported to 
cause heart failure (Schaefer et al 1995), high levels of cholesterol, particularly LDL 
cholesterol, are mainly responsible for hypercholesterolemia (Krieger 1998). Recently, 
hypercholesterolemia has been associated with enhanced oxidative stress related to 
increase lipid peroxidation (Adaramoye et al 2005). Increased generation of oxidized 
LDL is a major factor in the vascular damage associated with high cholesterol levels 
(Pritchard et al 1995). Hence, the inhibition of oxidative stress under hypercholester-
olemic conditions is considered to be an important therapeutic approach and efforts 
have been made to identify the antioxidative functions of various medicinal plants (Hu 
et al 2006; Tomotake et al 2006; Visavadiya and Narasimhacharya 2007).Vascular Health and Risk Management 2008:4(1) 236
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Drugs that lower cholesterol such as ﬁ  brates and bile 
acid sequestrants were used for several decades, but the high 
prevalence of their adverse effects led to the introduction of 
statins (HMG CoA inhibitors) (Miller 2001). Although the 
adverse effect of statins is relatively low, one rare effect called 
rhabdomyolysis can be very serious (Miller 2001). This effect 
is very pronounced when a statin is taken with another type 
of cholesterol lowering drug, in particular ﬁ  brates (Miller 
2001). Rhabdomyolysis led to the voluntary withdrawal of 
cerivastatin (Baycol) by its manufacturer. In view of the 
adverse effects associated with synthetic lipid-lowering drugs, 
the quest for natural products with lipid-lowering potential 
and with minimal or no side effect is warranted.
Plants have been the companions of man since time imme-
morial and formed the basis of useful drugs since they are 
less toxic than synthetic drugs. Screening of medicinal plants 
presents an avenue for the discovery of new drugs. Vernonia 
amygdalina (VA) is a shrub that grows predominantly in the 
tropical Africa. Leaves from this plant serve as food vegetable 
and culinary herb in soup (Argheore et al 1998). In Nigerian 
herbal homes, extracts of the plant are used as tonic, in the 
control of tick and treatment of cough, feverish condition, 
constipation and hypertension (Regassa 2000; Kambizi and 
Afolayan 2001; Amira and Okubadejo 2007). Phytochemical 
screening of VA revealed the presence of saponins, sesqui-
terpene, and ﬂ  avonoids (Igile et al 1994). Strong antioxidant 
activities have been reported for ﬂ  avonoids from VA and, its 
saponins have been reported to elicit antitumoral activities 
in leukemia cells (Jisaka et al 1993). Peptides from VA are 
known to be potent inhibitor of mitogen-activated proteins 
kinases, which are crucial for breast tumor growth and also 
represents a key regulatory point for the tumour (Izevbigie 
2003; Izevbigie and Ernest 2005). However, there is dearth 
of scientiﬁ  c data to support the folkloric use of this plant in 
the treatment of hypertension or related vascular diseases 
in Nigerian herbal homes. Therefore, the present work was 
designed to provide scientiﬁ  c proof of the use of VA in the 
treatment of vascular diseases.
Methods
Chemicals
Cholesterol and thiobarbituric acid (TBA) were procured 
from Aldrich Chemical Co. (Milwaukee, WI, USA). Questran 
(Bristol-Myers Squibb, Hounslow, UK) was purchased 
from a local chemist in Ibadan, Nigeria. Diagnostic kits for 
cholesterol and triglyceride were procured from Boehringer 
Mannheim GmbH Diagnostica, Germany. Other reagents 
were of analytical grade and the purest quality available.
Preparation of plant extract
Fresh leaves of Vernonia amygdalina were obtained from 
a local market, Sasa in Ibadan, Nigeria. The botanical 
identiﬁ  cation and authentication was conﬁ  rmed at the 
Department of Botany, University of Ibadan, Nigeria, where 
voucher specimen was kept at the herbarium (Voucher no. 
UI-02567). The leaves were air-dried at room temperature 
and then powdered. The powdered sample (1 kg) was de-
fatted with n-hexane (2.5 litres) and then extracted with 
75% methanol (2.5 litres) overnight in a soxhlet extractor 
(Sri Rudran Instrument Co, Chennai, India). The methanolic 
extract was concentrated and evaporated to dryness at 50 oC 
with a rotary evaporator under reduced pressure, and the 
yield of the preparation was 6.8%. The extract was dissolved 
in water at a concentration of 4 g/100 ml, and aliquots of 
different concentrations were given orally to the animals 
with a gavage needle.
Grouping of animals and study design
Forty-two male albino rats (Wistar strain) weighing between 
120–130 g were used as experimental animals. The rats 
were kept in cages in a room maintained at 26–29 °C with 
a 12-hour light-dark cycle for 4-weeks to acclimatize, and 
were allowed free access to food and water ad libitum. The 
protocol conforms to the guidelines of the National Institute 
of Health (NIH) (NIH publication 85–23, 1985) for laboratory 
animal care and use. Animals were randomly distributed into 
seven groups of six animals each. Group A served as control 
(received drug-vehicle, water), rats in groups B and C were 
administered VA at doses 100 and 200 mg/kg body weight, 
respectively in addition to oral administration of cholesterol. 
Rats in group D were intubated with cholesterol-only 
(hypercholesterolemic animals). Rats in group E served as 
positive control and were given VA at a dose of 100 mg/kg 
body weight, while rats in group F were intubated with 
cholesterol and Questran. Rats in group G were treated orally 
with Questran-only. Cholesterol was orally administered at 
a dose of 30 mg/0.3 ml/ animal, while Questran was given 
at a therapeutic dose of 0.26 g/kg body weight (Adaramoye 
et al 2005). Extract of VA was administered at doses 100 and 
200 mg/kg body weight (Iwalokun et al 2006). VA, Questran, 
and cholesterol were administered ﬁ  ve times in a week for a 
period of nine weeks.
Sample collection
After the last dose of drugs, rats were fasted overnight and 
sacrificed by cervical dislocation. Blood was collected 
from the heart into EDTA tubes. Plasma was prepared Vascular Health and Risk Management 2008:4(1) 237
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by centrifugation at 3,000 g for 15 minutes in an MSC bench 
centrifuge (Beckman and Hirsch, Burlington, IO, USA). The 
plasma was used in the estimation of lipid proﬁ  le. Liver from 
the animals were rinsed in ice- cold 1.15% KCl, dried and 
weighed. It was homogenized in 4 volumes of ice-cold 5 mM 
phosphate buffer, pH 7.4, and centrifuged at 10,000 g for 
20 min to obtain post mitochondrial fraction (PMF). Organs 
such as kidneys, lungs, liver and heart were removed from 
the animals and weighed.
Determination of triglyceride and cholesterol levels
Triglyceride and cholesterol levels were assayed using 
Boehringer Mannheim diagnostic kits.
Determination of protein and phospholipid levels
Protein level was determined by the method of Lowry 
and colleagues (1951). Brieﬂ  y, the method involved the 
reduction of phospho-18 molybdic tungstic complex 
by phenolic groups present in amino acids to blue 
precipitate at alkaline pH. The precipitate was read 
spectrophotometrically at 720 nm. The level of phospholipid 
was assayed by the method of Fiske and SubbaRow (1925). 
The method involves the release of inorganic phosphate 
from phospholipid in presence of an acceptor in aqueous 
medium. The inorganic phosphate reacts with ammonium 
molybdate and ascorbate to form a blue precipitate which 
was read at 660 nm spectrophotometrically.
Determination of HDL and LDL cholesterol levels
The lipoproteins, VLDL and LDL were precipitated using 
phosphotungstic acid and magnesium chloride. After cen-
trifugation, the supernatant contained the HDL fraction, 
which was assayed for cholesterol with diagnostic kit. LDL 
cholesterol was calculated using the formula of Friedewald 
and colleagues (1972).
Determination of lipid peroxidation (LPO) and 
reduced glutathione (GSH) levels
Lipid peroxidation and reduced glutathione levels were 
assayed by the methods of Walls and colleagues (1976) and 
Moron and colleagues (1979), respectively. Brieﬂ  y, GSH 
level was assayed by measuring the rate of formation of 
chromphoric product in a reaction between DTNB (5, 51-
dinitro bis (2-nitrobenzoic acid) and free sulphydryl groups 
(such as GSH) at 412 nm, while the extent of LPO was 
estimated by the measuring the intensity of pink precipitate 
formed in a reaction between malondialdehyde (MDA, 
end-product of lipid peroxidation) and thiobarbituric acid at 
535 nm spectrophotometrically.
Statistical analysis
Results were expressed as the mean ± S.D. (n = 6). A one- 
way analysis of variance (ANOVA) was used for the data 
analysis, using SPSS (Statistical Package for Social Sciences) 
(10.0) software. Signiﬁ  cant differences between groups were 
detected in the ANOVA using Duncan’s Multiple Range Test 
at p values less than 0.05 and 0.001.
Results
Table 1 depicts the effect of Vernonia amygdalina on body 
weight, organs weight and relative weight of visceral organs of 
hypercholesterolemic rats. Extract of VA at 100 and 200 mg/kg 
did not affect the body weight gain during this study. However, 
there was a signiﬁ  cant increase (p   0.001) in the body weight 
gain of hypercholesterolemic rats when compared with the 
control. In Table 2, there were signiﬁ  cant (p   0.001) increases 
in the plasma HDL cholesterol levels of animals treated with 
VA when compared with the hypercholesterolemic rats. Fur-
thermore, administration of cholesterol caused a signiﬁ  cant 
increase (p   0.05) in the plasma and PMF total cholesterol 
Table 1 Effect of Vernonia amygdalina on body weight, organ weight, and relative weight of visceral organs of hypercholesterolemic 
rats
Grouping  Body weight (g)    Lungs  Kidneys  Heart  Liver  Relative weight
       (g)  (g)  (g)  (g)  (%  body  weight)
 Initial  Final  Change          Heart  Liver
CONTROL 125.0  ± 5.2  171.0 ± 7.6  46.0 ± 8.6  1.6 ± 0.1  1.6 ± 0.1  0.80 ± 0.1  6.1 ± 0.5   0.47 ± 0.1  3.6 ± 0.4
VA1 + CH  120.2 ± 4.7  168.3 ± 5.7  48.1 ± 11.3  1.5 ± 0.4  1.5 ± 0.1  0.75 ± 0.1  5.8 ± 0.8  0.47 ± 0.1  3.7 ± 0.5
VA2 + CH  130.0 ± 4.5  174.0 ± 6.1  44.0 ± 5.5  1.6 ± 0.3  1.5 ± 0.3  0.82 ± 0.2  6.0 ± 0.6  0.47 ± 0.1  3.5 ± 0.3
CH ONLY  120.0 ± 3.0  178.3 ± 6.0  58.3 ± 6.0*  1.7 ± 0.3  1.8 ± 0.2  0.86 ± 0.2  6.2 ± 0.3  0.48 ± 0.1  3.5 ± 0.4
VA1 ONLY  120.3 ± 3.5  166.6 ± 4.3  46.3 ± 8.3  1.6 ± 0.3  1.8 ± 0.5  0.80 ± 0.2  6.1 ± 0.7  0.48 ± 0.0  3.7 ± 0.4
QU + CH  125.0 ± 4.3  170.0 ± 7.9  45.0 ± 7.2  1.5 ± 0.1  1.6 ± 0.2  0.82 ± 0.1  5.9 ± 0.5  0.48 ± 0.1  3.5 ± 0.5
QU ONLY  130.0 ± 5.8  176.0 ± 8.7  46.0 ± 8.8  1.7 ± 0.2  1.7 ± 0.4  0.79 ± 0.1  6.0 ± 0.6  0.45 ± 0.1  3.4 ± 0.5
Notes: Values are means ± S.D. of six animals; *Signiﬁ  cantly different at p   0.001 from others.
Abbreviations: VA, Vernonia amygdalina; CH, cholesterol; QU, Questran;  VA1, 100 mg/kg; VA2, 200 mg/kg.Vascular Health and Risk Management 2008:4(1) 238
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and triglyceride levels of the rats (Figures 1 and 2). Precisely, 
plasma and PMF levels of total cholesterol and triglyceride 
were increased by 33%, 55% and 44%, 80%, respectively. The 
hypercholesterolemia induced by the dietary cholesterol was 
signiﬁ  cantly attenuated (p   0.05) in animals treated with VA 
and Questran. Furthermore, VA at a dose of 200 mg/kg was 
able to decrease the hypertriglyceridemia induced by dietary 
cholesterol (Figure 2). Administration of dietary cholesterol 
signiﬁ  cantly (p   0.05) increased plasma and PMF LPO by 
58% and 90%, respectively (Figure 3). However, the choles-
terol-induced increase in plasma and PMF LPO was signiﬁ  -
cantly (p   0.05) attenuated by extract of VA. Speciﬁ  cally, 
VA at 100 and 200 mg/kg decreased the plasma and PMF 
LPO by 38%, 42% and 35%, 45%, respectively. Table 2 and 
Figure 4 show that cholesterol administration signiﬁ  cantly 
(p   0.05) elevated the plasma and PMF LDL cholesterol 
levels of hypercholesterolemic rats. Speciﬁ  cally, plasma and 
PMF LDL cholesterol levels were elevated by 41% and 115%, 
respectively. However, VA at 200 mg/kg signiﬁ  cantly attenu-
ated (p   0.05) the cholesterol-induced increase in plasma and 
PMF LDL cholesterol by 23% and 49%, respectively. Similarly, 
the cholesterol-induced decrease in PMF reduced glutathione 
levels of hypercholesterolemic rats were signiﬁ  cantly (p   0.05) 
ameliorated in animals treated with VA (Figure 4).
Discussion
The presence of a high amount of cholesterol in the diet 
has been demonstrated to elevate plasma cholesterol and 
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Figure 1 Effect of Vernonia amygdalina on plasma and post mitochondrial fraction (PMF) cholesterol levels of hypercholesterolemic rats.
Note: *Signiﬁ  cantly different from CH group at p   0.05. 
Abbreviations: CH, Cholesterol;   VA, Vernonia amygdalina; QU, Questran; PMF, Post mitochondrial fraction;   VA1, 100 mg/kg;   VA2, 200 mg/kg.
Table 2 Effect of Vernonia amygdalina on protein, phospholipid, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) 
cholesterol levels of hypercholesterolemic rats
Grouping Protein  content  Phospholipid  HDL-cholesterol  LDL-cholesterol
 Plasma  PMF  PMF  Plasma  PMF  PMF 
  (g/ml)  (mg/g liver)  (mg/dL)  (mmol/L)  (mmol/g liver)  (mmol/g liver)
CONTROL 7.0  ± 1.3  2.4 ± 0.3  542.8 ± 13.6  0.28 ± 0.07*  0.09 ± 0.02  2.9 ± 0.9**
VA1 + CH  6.8 ± 1.4  2.8 ± 0.8  532.5 ± 10.3  0.24 ± 0.04*  0.10 ± 0.02  4.8 ± 1.2
VA2 + CH  6.5 ± 1.8  2.1 ± 0.6  535.7 ± 16.7  0.27 ± 0.06*  0.10 ± 0.02  3.2 ± 1.2**
CH ONLY  6.1 ± 1.5  2.4 ± 0.3  545.2 ± 11.4  0.17 ± 0.03  0.09 ± 0.02  6.2 ± 0.8
VA1 ONLY  6.2 ± 0.6  2.5 ± 0.5  548.6 ± 11.9  0.28 ± 0.05*  0.09 ± 0.01  2.6 ± 0.8**
QU + CH  6.5 ± 1.4  2.6 ± 1.5  547.8 ± 14.6  0.19 ± 0.05  0.08 ± 0.02  5.0 ± 1.4
QU ONLY  6.0 ± 0.5  2.5 ± 0.5  536.5 ± 13.8  0.26 ± 0.05*  0.09 ± 0.01  3.2 ± 0.9**
Notes: Values are means ± S.D. of six animals; *Signiﬁ  cantly different from CH group at p   0.001; **Signiﬁ  cantly different from CH group at p   0.05.
Abbreviations: VA, Vernonia amygdalina; CH, cholesterol; QU, Questran; PMF, post mitochondrial fraction;   VA1, 100 mg/kg; VA2, 200 mg/kg. Vascular Health and Risk Management 2008:4(1) 239
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may increase aortic atherosclerosis (LRCP 1984). Several 
studies have indicated that diet treatment or drug therapy to 
regulate cholesterol can reduce subsequent CVD-associated 
mortality and morbidity (Kwiterovich 1997). On the basis 
of this, great efforts have been made to reduce the risk 
of CVD through the regulation of cholesterol, thus the 
therapeutic beneﬁ  ts of plant foods have been the focus 
of many extensive dietary studies (Yokozawa et al 2006; 
Zhang et al 2007).
In the present study, we investigated the lipid-lowering 
effects of Vernonia amygdalina in rats fed on high cho-
lesterol diet for a period of nine weeks. Notably, the rats 
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Figure 2 Effect of Vernonia amygdalina on plasma and post mitochondrial fraction (PMF) triglyceride levels of hypercholesterolemic rats.
Note: *Signiﬁ  cantly different from CH group at p   0.05.
Abbreviations: CH, Cholesterol;   VA, Vernonia amygdalina; QU, Questran; PMF, Post mitochondrial fraction;   VA1, 100 mg/kg; VA2, 200 mg/kg.
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Figure 3 Effect of Vernonia amygdalina on plasma and post mitochondrial fraction (PMF) lipid peroxidation levels of hypercholesterolemic rats.
Note: *Signiﬁ  cantly different from CH group at p   0.05. 
Abbreviations: CH, Cholesterol; VA,   Vernonia amygdalina; QU, Questran; LPO, Lipid peroxidation;   VA1, 100 mg/kg; VA2, 200 mg/kg.Vascular Health and Risk Management 2008:4(1) 240
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intubated with dietary cholesterol showed higher plasma 
and hepatic levels of total cholesterol and triglyceride than 
the extract-treated animals. It is obvious that the reducing 
effect produced by Vernonia amygdalina on plasma and PMF 
cholesterol levels is dose dependent. Dietary cholesterol 
has been shown to reduce fatty acid oxidation, which, in 
turn, increases the levels of hepatic and plasma triglycerol 
(Fungwe et al 1993). The elevated levels of plasma and 
PMF triglyceride obtained in cholesterol-fed rats are in line 
with the ﬁ  ndings of Adaramoye and colleagues (2005) and 
Yokozawa and colleagues (2006). The results suggest that VA 
(200 mg/kg) reduced the hepatic triglyceride biosynthesis and 
favour the redistribution of cholesterol among the lipoprotein 
molecules. This observation is consistent with the ﬁ  ndings 
of Nwanjo (2005) in which VA signiﬁ  cantly attenuated the 
hepatic triglyceride and LDL cholesterol levels of strepto-
zotocin diabetic rats.
The crucial risk factor for CVD includes a low level 
of HDL-cholesterol. The association between a low level 
of HDL-cholesterol and an increased risk of CVD has 
been well established through epidemiological and clinical 
studies (Assmann and Gotto 2004). Since low level of HDL-
cholesterol plays a direct role in the atherogenic process, 
therapeutic intervention to raise HDL-cholesterol together 
with other risk factors is widely encouraged. In this study, 
treatment with VA led to signiﬁ  cant elevation of plasma 
HDL-cholesterol, indicating its promising protective role 
against CVD. The protective roles of HDL cholesterol from 
CVD have been suggested to occur in various ways (Nofer 
et al 2002). HDL exerts part of its anti-atherogenic effect 
by counteracting LDL oxidation and, recent studies also 
showed that HDL promotes the reverse cholesterol transport 
pathway, by inducing an efﬂ  ux of excess accumulated cellular 
cholesterol and prevents the generation of an oxidatively 
modiﬁ  ed LDL (Yokozawa et al 2006). Furthermore, HDL 
inhibits the oxidation of LDL by transition metal ions, but 
also prevents 12-lipooxygenase-mediated formation of lipid 
hydroperoxides (Nofer et al 2002). On the basis of our results, 
VA may probably plays an anti-atherogenic role through the 
inhibition of lipids oxidation, (due to its anti-lipoperoxidative 
effect observed in this study) as well as the elevation of HDL 
cholesterol.
LDL cholesterol is another primary target of CVD risk-
reduction therapy (Kwiterovich 1997). In this study, VA 
administered at a dose of 200 mg/kg lowered LDL cholesterol 
levels of hypercholesterolemic rats. Excess LDL can be 
deposited in the blood vessel walls and becomes a major 
component of atherosclerotic plaque lesions. Therefore, 
plasma LDL cholesterol level may be used for monitoring 
the treatment of patients with elevated blood cholesterol 
levels. In view of our results, VA elicited beneﬁ  cial effects by 
lowering the plasma and PMF levels of cholesterol including 
low-density lipoprotein of the treated rats. Oxidative stress, 
deﬁ  ned as a disruption of the balance between oxidative 
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Figure 4 Effect of Vernonia amygdalina on plasma LDL-cholesterol and post mitochondrial fraction (PMF) reduced glutathione levels of hypercholesterolemic rats.
Note: *Signiﬁ  cantly different from CH group at p  0.05. 
Abbreviations: CH, Cholesterol;   VA,   Vernonia amygdalina; QU, Questran; LDL, Low-density lipoprotein; PMF, Post mitochondrial fraction; GSH, Reduced glutathione; 
VA1, 100 mg/kg;   VA2, 200 mg/kg.Vascular Health and Risk Management 2008:4(1) 241
Lipid-lowering effects of Vernonia amygdalina
and antioxidative processes, plays an important role in the 
pathogenesis of atherosclerosis (Yokozawa et al 2006). 
A cholesterol rich diet results in increased lipid peroxidation, 
followed by hypercholesterolemia (Adaramoye et al 2005). 
The relationship between oxidative stress and cholesterol 
level was conﬁ  rmed in the present study, in which the 
hepatic glutathione (GSH), an indicator of antioxidant 
defense, exhibited a negative correlation with the hepatic 
total cholesterol levels of hypercholesterolemic rats, but a 
positive correlation with the cholesterol levels of extract-
pretreated rats. Therefore, VA may elicit some health beneﬁ  ts 
through the modulation of physiologic functions including 
the atherogenic lipid proﬁ  le.
Evidence from this study conﬁ  rms the lipid-lowering 
effects of VA in rats fed on high cholesterol diet. VA at 
200 mg/kg was effective in reducing the levels of plasma 
and PMF total cholesterol as well as low-density lipoprotein 
cholesterol. Further studies are warranted to determine the 
exact component in VA responsible for the observed effect 
and, such component may be a candidate for use as a prophy-
lactic agent against hypercholesterolemia.
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